|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Ramipril#Use in Specific Populations]] |
| {{Ramipril}}
| |
| {{CMG}}; {{AE}} {{AM}}
| |
| | |
| ==Use in Specific Populations==
| |
| | |
| ====Pregnancy====
| |
| | |
| ====Pregnancy Category D====
| |
| | |
| Use of drugs that act on the [[renin-angiotensin system]] during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting [[oligohydramnios]] can be associated with [[fetal lung hypoplasia]] and skeletal deformations. Potential neonatal adverse effects include [[skull hypoplasia]], [[anuria]], [[hypotension]], [[renal failure]], and death. When pregnancy is detected, discontinue ALTACE as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.
| |
| | |
| In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue ALTACE unless it is considered life-saving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to ALTACE for [[hypotension]], [[oliguria]], and [[hyperkalemia]].
| |
| | |
| ====Nursing Mothers====
| |
| Ingestion of a single 10 mg oral dose of ALTACE resulted in undetectable amounts of ramipril and its metabolites in breast milk. However, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ALTACE in nursing mothers.
| |
| | |
| | |
| ====Pediatric Use====
| |
| | |
| =====Neonates with a history of in utero exposure to ALTACE=====
| |
| | |
| If [[oliguria]] or [[hypotension]] occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or [[dialysis]] may be required as a means of reversing hypotension and/or substituting for disordered renal function. Ramipril, which crosses the placenta, can be removed from the [[[neonatal circulation]] by these means, but limited experience has not shown that such removal is central to the treatment of these infants.
| |
| | |
| Safety and effectiveness in pediatric patients have not been established. Irreversible kidney damage has been observed in very young rats given a single dose of ALTACE.
| |
| | |
| | |
| ====Geriatric Use====
| |
| Of the total number of patients who received ALTACE in U.S. clinical studies of ALTACE, 11.0% were ≥65 years of age while 0.2% were ≥75 years of age. No overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.
| |
| | |
| One pharmacokinetic study conducted in hospitalized elderly patients indicated that peak ramiprilat levels and area under the plasma concentration-time curve (AUC) for ramiprilat are higher in older patients.
| |
| | |
| | |
| ====Renal Impairment====
| |
| A single-dose pharmacokinetic study was conducted in hypertensive patients with varying degrees of renal impairment who received a single 10 mg dose of ramipril. Patients were stratified into four groups based on initial estimates of [[creatinine clearance]]: normal (>80 mL/min), mild impairment (40–80 mL/min), moderate impairment (15–40 mL/min), and severe impairment (<15 mL/min). On average, the AUC0–24h for ramiprilat was approximately 1.7-fold higher, 3.0-fold higher, and 3.2-fold higher in the groups with mild, moderate, and severe renal impairment, respectively, compared to the group with normal renal function. Overall, the results suggest that the starting dose of ramipril should be adjusted downward in patients with moderate-to-severe renal impairment.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTACE (RAMIPRIL) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0fc34cd8-86e6-4034-73bd-4263a68ba046 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |